medtechdive2h
Novocure wins FDA approval for electric field device in lung cancer
Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
FierceBiotech2d
Novocure nets FDA approval for Tumor Treating Fields in metastatic lung cancer
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...
Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment
Optune Lua is a wearable device for which tumor-treating fields (TTFields) inhibit the proliferation and metastasis of lung ...
Business Wire2d
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...
Novocure gets FDA approval for its lung cancer treatment
Novocure (NASDAQ:NVCR) shares rose 6% after market on announcing U.S. FDA approval for Optune Lua for the treatment of adult ...
Morningstar3d
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
“Novocure is committed to extending survival ... Optune Lua is a portable device that produces alternating electric fields known as tumor treating fields (TTFields), which are delivered through ...
Investing2d
FDA approves new NSCLC treatment Optune Lua
TTFields are alternating electric fields that disrupt the division ... cancer through its Tumor Treating Fields therapy. In financial developments, Novocure reported a rise in its second quarter ...
Targeted Oncology2d
FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in Metastatic NSCLC
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
Investor's Business Daily on MSN2d
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment
Novocure stock rocketed late Tuesday after the FDA signed off on its treatment for patients with metastatic lung cancer.
Investing18d
Novocure's SWOT analysis: oncology firm's stock faces growth hurdles, pipeline promise
Its approach utilizes Tumor Treating Fields (TTFields) therapy, which disrupts cancer cell division through the application of electric fields. In the second quarter of 2024, Novocure demonstrated ...
BioSpace3d
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
Optune Lua is a portable device that produces alternating electric fields known as tumor treating ... the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s ...
Investing3d
FDA approves new NSCLC treatment Optune Lua
TTFields are alternating electric fields that disrupt the division of cancer ... in aggressive forms of cancer through its Tumor Treating Fields therapy. In financial developments, Novocure reported a ...